EN | UA
EN | UA

Help Support

Back

Tirzepatide shows impressive weight reduction results

Weight loss Weight loss
Weight loss Weight loss

What's new?

Tirzepatide can be a promising therapy for weight loss in people with obesity and diabetes.

A recent study published in the “Journal of the Endocrine Society” highlights the impressive weight reduction results of Tirzepatide, a novel dual gastric inhibitory polypeptide/glucagon-like peptide-1 (GIP/GLP-1) receptor agonist approved for treating type 2 diabetes (T2D). The study, conducted as a retrospective cohort analysis by Sima Fansa et al., focused on assessing the real-world effectiveness and safety of Tirzepatide in 175 patients taking weekly subcutaneous Tirzepatide for T2D or off-label for weight loss.

The researchers excluded individuals taking Tirzepatide for less than one month, those with a history of bariatric procedures, the use of anti-obesity prescriptions, or individuals with active malignancies or pregnancy. The total body weight loss percentage (TBWL%) at three months was considered as the main outcome, while secondary outcomes included TBWL% at one and two months; TBWL% difference by T2D status and by gender; percentage of patients achieving more than equal to 5%, 10% and 15% of TBWL% at 3 months; predictors of TBWL% at 3 months; and adverse-effects.

Researchers employed a paired t-test to assess TBWL% in relation to the baseline, utilized a non-paired t-test to compare TBWL% based on T2D status and gender, and conducted univariate analyses to gauge the impact of other variables on TBWL%. The findings were presented as the mean ± standard deviation. A total of 59 patients, accounting for 34% of the cohort, had T2D. The majority of patients were prescribed either 5 mg (39%) or 7.5 mg (22%) of Tirzepatide on a weekly basis.

The TBWL% at 1, 2, and 3 months stood at 3.6±2.5% (involving 87 patients), 5.8±3.5% (involving 100 patients), and 8.4±4.3% (involving 60 patients), respectively (with a p-value of <0.0001 compared to the baseline at all three timepoints). At the 3-month mark, patients with T2D experienced a lower weight loss compared to patients without T2D: 6.9±4.0% vs 9.1±4.4% (with a p-value of 0.03).

Also, females experienced greater weight loss than males after 3 months  (9.2±4.3% vs. 5.0±2.5%). The researchers observed that greater baseline weight was associated with more significant TBWL%, indicating the drug's effectiveness in aiding individuals with higher initial body weights. After 3 months, weight measurements were available for 60 patients. Among them, 81.6% achieved a TBWL of 5% or more, while 30% achieved a TBWL of 10% or more, and 10% achieved a TBWL of 15% or more.

Side effects were reported by 23% of the participants (the most common being nausea/vomiting, constipation, and pain in the abdomen). A small portion of patients had to adjust their dosage or discontinue the drug because of side effects. Extended follow-up durations and higher doses of Tirzepatide are required to establish the long-term effectiveness of this drug in treating obesity and T2D simultaneously, concluded the study researchers.

Source:

Journal of the Endocrine Society

Article:

FRI078 Real-World Weight Loss Outcomes And Safety Of Tirzepatide, A Novel Dual GIP And GLP-1 Receptor Agonist

Authors:

Sima Fansa et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru ua
Try: